Biostatistics

“Exploristics has provided excellent service on the Bayesian extrapolation of efficacy in pediatric patients. This is a highly technical expertise that several preferred vendors could not provide when we sought bids from them for this project. The statistical analysis proposal was very clear and cogent that I believe would meet PDCO expectations to discharge the PIP commitment when the regulatory report is filed. I can’t say enough it was an absolute pleasure to work with the team at Exploristics!”

“It was a great pleasure working with you. Your professionalism, creativity and patience helped us in providing solutions to the nonstandard problems we are facing. Although further work is needed, we can already demonstrate the positive impact of your contribution to our projects.”

“We have been very pleased with the work done. The Exploristics team listened to what we needed from the project and helped us address those questions. I feel we have good information on which to build our clinical study. When we met up, the data was presented to us clearly and we had good, open discussions. Our questions were either answered in the meeting or followed up on after. Agreed timelines for the work were met and we were kept updated during the process.”

“Our experience of working with Exploristics was overwhelmingly positive. The thinking around the company’s objectives from the study took it beyond a number crunching exercise to a more informed and nuanced service that added value to the study and the business. I was also impressed by the flexibility on responding to questions from the Board and others to get us over the line. I hope we have a reason to work together again.”

“With Exploristics, we are cultivating an important partnership that grows as we develop our programme across multiple studies and indications. They offer highly skilled people who are a pleasure to work with. They are very responsive and are able to quickly react to ad hoc requests facilitated by a nimble contracting process.”

“The company was very pleased to receive orphan drug designation in both the US and EU. The EMA cited clinically relevant biomarker data as a justification for the designation. The data presented provided evidence of a clinically relevant advantage over existing treatments, offering the potential to address a significant unmet medical need.”